GlassScriptPhysician profile
Paul J Simpson
NPI 1043530942
$1,693.33
in general payments reported to CMS, 2019-2025
25 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $62.73 · 2021: $41.39 · 2022: $64.33 · 2023: $412 · 2024: $833 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.94 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.70 | 2023-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $153.89 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $92.11 | 2024 | |
| Glaxosmithkline, LLC. | $88.30 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $77.25 | 2024 | Breztri |
| Astellas Pharma US INC | $76.95 | 2019-2024 | Veozah |
| Organogenesis INC. | $64.83 | 2019-2022 | |
| Smith+Nephew, INC. | $61.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $45.58 | 2024-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Kerecis Limited | $44.94 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Urgo Medical North America, LLC | $43.45 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Pfizer INC. | $39.34 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.10 | 2020-2023 | |
| Integra Lifesciences Corporation | $35.29 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.45 | 2025 | Eliquis |
| Kci USA, INC. | $22.30 | 2020 | |
| Lifenet Health | $19.57 | 2023 | |
| Amgen INC. | $18.53 | 2025 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $18.07 | 2023 | Auvelity |
| Acera Surgical, INC. | $17.73 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.62 | 2019 | |
| Lilly USA, LLC | $13.28 | 2023 | Mounjaro |
| Phadia US INC. | $13.14 | 2023 | Immunocap |
| Shire North American Group INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.